Can an Adult Female Increase Vyvanse from 60mg to 70mg?
Yes, an adult female tolerating Vyvanse 60 mg well can be increased to 70 mg, as this is within the FDA-approved maximum dosage for ADHD treatment in adults. 1
FDA-Approved Dosing
The FDA label for Vyvanse explicitly states that for ADHD treatment in adults, dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals up to a maximum recommended dosage of 70 mg once daily 1. Since your patient is currently at 60 mg and tolerating it well, a 10 mg increase to the maximum dose of 70 mg is appropriate if symptom control remains suboptimal.
Evidence Supporting Higher Doses
Research demonstrates that higher doses of lisdexamfetamine lead to greater improvements in ADHD symptoms, with this dose-response relationship holding across the 30-70 mg range 2. Importantly, patients with greater baseline symptom severity may benefit more from higher doses, particularly for hyperactive-impulsive symptoms 2, 3.
In long-term studies, patients across all severity levels showed sustained efficacy at doses up to 70 mg, with 81.6-88.4% of patients achieving "very much/much improved" status on Clinical Global Impressions scales 3. The safety profile remained consistent with long-acting stimulant use throughout the therapeutic dose range 3.
Clinical Decision Algorithm
Increase to 70 mg if:
- Current symptoms remain inadequately controlled at 60 mg
- No significant cardiovascular concerns (blood pressure and pulse should be monitored quarterly in adults) 4
- No problematic side effects at current dose (insomnia, decreased appetite, irritability)
- Patient has good medication adherence
Do NOT increase if:
- Adequate symptom control already achieved at 60 mg
- Significant side effects present (decreased appetite, insomnia, cardiovascular changes)
- Renal impairment: severe renal impairment limits maximum dose to 50 mg; end-stage renal disease limits to 30 mg 1
Important Monitoring Considerations
Before increasing the dose, ensure:
- Quarterly blood pressure and pulse checks are current (required for adults on stimulants) 4
- Systematic assessment of known side effects: insomnia, anorexia, headaches, irritability 4
- Patient weight monitoring if appetite suppression is present 4
- Review of any medications that alter urinary pH (acidifying agents decrease amphetamine levels; alkalinizing agents increase them) 1
Pharmacokinetic Rationale
Lisdexamfetamine follows linear pharmacokinetics at therapeutic doses (30-70 mg) 5. The prodrug is converted to d-amphetamine in the blood, with d-amphetamine levels peaking at approximately 4.4 hours post-dose and maintaining a half-life of 10-11.3 hours in adults 6, 5. This provides full-day coverage without the abuse potential of immediate-release formulations 7.
Common Pitfalls to Avoid
- Don't assume "more is better": If 70 mg doesn't provide adequate control, consider switching medications or adding psychosocial interventions rather than exceeding the maximum approved dose 4
- Don't ignore cardiovascular monitoring: Adults require quarterly BP/pulse checks, not just annual physicals 4
- Don't overlook drug interactions: Agents altering urinary pH can significantly impact amphetamine blood levels and may require dose adjustment 1
The increase from 60 mg to 70 mg represents a standard, evidence-based titration within FDA guidelines and should be considered if symptom control warrants optimization.